Relationship between corticotherapy and increased cardiac risk in patients with rheumatoid arthritis

Elisangela Gueiber Montes; Fabiana Postiglione Mansani; Marcelo Derbli Schafranski; Alceu de Oliveira Toledo Júnior; Lorena de Freitas Calixto; Rômulo Lopes da Costa; Rodrigo Luiz Staichak; Francine Marques Pinto; Juliane de Lara Berso; Nicole  Guimarães; Marcos Noris Bernardes de Souza; Bruno Queiroz Zardo; José Carlos Rebuglio Vellosa

doi:10.1590/s2175-97902020000419156

Authors

Elisangela Gueiber Montes Clinical and Toxicological Analysis Department, State University of Ponta Grossa, UEPG, Ponta Grossa, PR, Brazil,
Fabiana Postiglione Mansani Medicine Department, State University of Ponta Grossa, UEPG, Ponta Grossa, PR, Brazil
Marcelo Derbli Schafranski Medicine Department, State University of Ponta Grossa, UEPG, Ponta Grossa, PR, Brazil https://orcid.org/0000-0003-1694-085X
Alceu de Oliveira Toledo Júnior Clinical and Toxicological Analysis Department, State University of Ponta Grossa, UEPG, Ponta Grossa, PR, Brazil,
Lorena de Freitas Calixto Medicine Department, State University of Ponta Grossa, UEPG, Ponta Grossa, PR, Brazil
Rômulo Lopes da Costa Medicine Department, State University of Ponta Grossa, UEPG, Ponta Grossa, PR, Brazil
Rodrigo Luiz Staichak Medicine Department, State University of Ponta Grossa, UEPG, Ponta Grossa, PR, Brazil
Francine Marques Pinto Medicine Department, State University of Ponta Grossa, UEPG, Ponta Grossa, PR, Brazil
Juliane de Lara Berso Medicine Department, State University of Ponta Grossa, UEPG, Ponta Grossa, PR, Brazil
Nicole Guimarães Clinical and Toxicological Analysis Department, State University of Ponta Grossa, UEPG, Ponta Grossa, PR, Brazil, 2 Medicine Department, State University of Ponta Grossa, UEPG, Ponta Grossa, PR, Brazil
Marcos Noris Bernardes de Souza Medicine Department, State University of Ponta Grossa, UEPG, Ponta Grossa, PR, Brazil
Bruno Queiroz Zardo Medicine Department, State University of Ponta Grossa, UEPG, Ponta Grossa, PR, Brazil
José Carlos Rebuglio Vellosa 1 Clinical and Toxicological Analysis Department, State University of Ponta Grossa, UEPG, Ponta Grossa, PR, Brazil, https://orcid.org/0000-0003-4747-9197

DOI:

https://doi.org/10.1590/s2175-97902020000419156

Keywords:

Cardiovascular risk. Glucocorticoids. Rheumatoid arthritis.

Abstract

Rheumatoid arthritis is an autoimmune inflammatory joint disease with global prevalence of 0.4% to 1.0%. Extra-articular manifestations increase its morbidity and severity, and cardiovascular diseases present the greatest risk. Therapeutic approaches have been used to treat rheumatoid arthritis, often involving the use of multiple classes of drugs with different mechanisms and forms of action. Corticosteroid therapy is widely used in this therapeutic combination; however, its use has been widely questioned because of its high toxicity and some negative effects, including the possibility of increased cardiovascular risk, depending on the dosage. Some studies have provided important insights into how glucocorticoids have an impact on cardiac complications in patients with rheumatoid arthritis. Most of these studies have concluded that exposure to these drugs at high or cumulative doses is associated with increased risk of death, as well as possibly being associated with the presence of a positive rheumatoid factor.

Downloads

Download data is not yet available.

References

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580-8.

Amaya-Amaya J, Sarmiento-Monroy JC, Mantilla RD, Pineda-Tamayo R, Rojas-Villarraga A, Anaya JM. Novel risk factors for cardiovascular disease in rheumatoid arthritis. Immunol Res. 2013;56(2-3):267-86.

Arias de la Rosa I, Escudero-Contreras A, RodríguezCuenca S, Ruiz-Ponce M, Jiménez-Gómez Y, Ruiz-Limón P, et al. Defective glucose and lipid metabolism in rheumatoid arthritis is determined by chronic inflammation in metabolic tissues. J Intern Med. 2018.

Aviña-Zubieta JA, Abrahamowicz M, De Vera MA, Choi HK, Sayre EC, Rahman MM, et al Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a populationbased study. Rheumatology (Oxford). 2013;52(1):68-75.

Bartoloni E, Alunno A, Gerli R. Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases. Nat Rev Cardiol. 2018;15(1):33-44.

Birru Talabi M, Mackey RH, Kuller LH, Dorman JS, Deane KD, Robinson WH, et al. Hla-shared epitope, inflammation, mortality, cvd and malignancy among postmenopausal women with and without rheumatoid arthritis in the women’s health. Am J Epidemiol. 2017;186(2):245-254.

Black RJ, Goodman SM, Ruediger C, Lester S, Mackie SL, Hill CL. A survey of glucocorticoid adverse effects and benefits in rheumatic diseases: the patient perspective. J Clin Rheumatol. 2017;23(8):416-420.

Braun J, Krüger K, Manger B, Schneider M, Specker C, Trappe HJ. Cardiovascular Comorbidity in Inflammatory Rheumatological Conditions. Dtsch Arztebl Int. 2017;114(12):197-203.

Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 2004;50(11):3408-17.

Chiu HY, Huang HL, Li CH, Chen HA, Yeh CL, Chiu SH, et al Increased Risk of Chronic Kidney Disease in Rheumatoid Arthritis Associated with Cardiovascular Complications - A National Population-Based Cohort Study. PLoS One. 2015;10(9):e0136508.

Davis JM, Maradit Kremers H, Crowson CS, Nicola PJ, Ballman KV, Therneau TM, et al Glucocorticoids and cardiovascular events in rheumatoid arthritis: a populationbased cohort study. Arthritis Rheum. 2007;56(3):820-30.

del Rincón I, Battafarano DF, Restrepo JF, Erikson JM, Escalante A. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum. 2014;66(2):264-72.

Dessein PH, Joffe BI, Stanwix AE, Christian BF, Veller M. Glucocorticoids and insulin sensitivity in rheumatoid arthritis. J Rheumatol. 2004; 31(5):867-74.

Dessein PH, Tobias M, Veller MG. Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol. 2006; 33(12):2425-32.

El Bakry SA, Fayez D, Morad CS, Abdel-Salam AM, AbdelSalam Z, El Kabarity RH, et al. Ischemic heart disease and rheumatoid arthritis: Do inflammatory cytokines have a role? Cytokine. 2017;96:228-33.

Ferreira JF, Ahmed Mohamed AA, Emery P. Glucocorticoids and Rheumatoid Arthritis. Rheum Dis Clin North Am. 2016;42(1):33-46, vii.

García-Gómez C, Nolla JM, Valverde J, Narváez J, Corbella E, Pintó X. High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy. Eur J Clin Invest. 2008;38(9):686-92.

Gullick NJ, Scott DL. Co-morbidities in established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2011;25(4):469-83.

Haque S, Mirjafari H, Bruce IN. Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Curr Opin Lipidol. 2008;19(4):338-43.

Hunter TM, Boytsov NN, Zhang X, Schroeder K, Michaud K, Araujo AB. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 20042014. Rheumatol Int. 2017;37(9):1551-1557.

Kirwan BJ, Gunasekera W. Is There a Renaissance of Glucocorticoids in Rheumatoid Arthritis? Clin Pharmacol Ther. 2017;102(4):574-7.

Kirwan Jr BJ, Boers M, Shea B. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. 2009.

Lauper K, Gabay C. Cardiovascular risk in patients with rheumatoid arthritis. Semin Immunopathol. 2017;39(4):447-59.

Li HB, Bai L, Wu QJ, Zhang X, Zhang FC. [Risk factor assessment of cardiocerebrovascular diseases in patients with rheumatoid arthritis]. Zhonghua Yi Xue Za Zhi. 2006;86(25):1769-73.

Li Wei M, MSc. Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease. In: Thomas M. MacDonald M, FRCPE, Brian R. Walker M, FRCPE, editors. 2004

Mazzantini M, Talarico R, Doveri M, Consensi A, Cazzato M, Bazzichi L, et al. Incident comorbidity among patients with rheumatoid arthritis treated or not with lowdose glucocorticoids: a retrospective study. J Rheumatol. 2010;37(11):2232-6.

Naranjo A, Sokka T, Descalzo MA, Calvo-Alén J, HørslevPetersen K, Luukkainen RK, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUESTRA study. Arthritis Res Ther. 2008;10(2):R30.

Negrei C, Bojinca V, Balanescu A, Bojinca M, Baconi D, Spandidos DA, et al. Management of rheumatoid arthritis: Impact and risks of various therapeutic approaches. Exp Ther Med. 2016;11(4):1177-83.

Ortega-Hernandez OD, Pineda-Tamayo R, Pardo AL, Rojas-Villarraga A, Anaya JM. Cardiovascular disease is associated with extra-articular manifestations in patients with rheumatoid arthritis. Clin Rheumatol. 2009;28(7):767-75.

Park YB, Ahn CW, Choi HK, Lee SH, In BH, Lee HC, et al. Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum. 2002;46(7):1714-9.

Patel R, Magomedova L, Tsai R, Angers S, Orellana A, Cummins CL. Separating the Anti-Inflammatory and Diabetogenic Effects of Glucocorticoids Through LXRβ Antagonism. Endocrinol. 2017;158(4):1034-47.

Radhakutty A, Mangelsdorf BL, Drake SM, SamochaBonet D, Jenkins AB, Heilbronn LK, et al. Effect of acute and chronic glucocorticoid therapy on insulin sensitivity and postprandial vascular function. Clin Endocrinol (Oxf). 2016;84(4):501-8.

Ruyssen-Witrand A, Fautrel B, Saraux A, Le Loët X, Pham T. Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine. 2011;78(1):23-30.

Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheum. 2016;68(1):1-26.

Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F, et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther. 2009;11(1):R7.

Udachkina HV, Novikova DS, Popkova TV, Kirillova IG, Markelova EI, Luchikhina EL, et al. Calcification of coronary arteries in early rheumatoid arthritis prior to anti-rheumatic therapy. Rheumatol Int. 2017.

Unnikrishnan R, Pradeepa R, Joshi SR, Mohan V. Type 2 Diabetes: Demystifying the Global Epidemic. Diabetes. 2017;66(6):1432-42.

Verhoeven F, Prati C, Maguin-Gaté K, Wendling D, Demougeot C. Glucocorticoids and endothelial function in inflammatory diseases: focus on rheumatoid arthritis. Arthritis Res Ther. 2016;18(1):258.

Verma I, Syngle A, Krishan P. Predictors of endothelial dysfunction and atherosclerosis in rheumatoid arthritis in Indian population. Indian Heart J. 2017;69(2):200-6.

Relationship between corticotherapy and increased cardiac risk in patients with rheumatoid arthritis

Authors

DOI:

Keywords:

Abstract

Downloads

References

Downloads

Published

Issue

Section

License

How to Cite